<strong>Background:</strong><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> There is ample evidence...<strong>Background:</strong><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> There is ample evidence to support the safety and efficacy of the topical anticancer cream Curaderm in the treatment of non-melanoma skin cancers. Curaderm contains the natural glycoalkaloid solamargine in the form of BEC, which has been established as a novel antineoplastic agent. BEC is the initials of the inventor of the described technology. It is known that BEC expresses anti-melanoma properties in cell culture and animals. Because of potential metastasis, clinical work with BEC on melanoma was stalled. However, recent studies show that BEC has anti-metastatic properties and this, together with currently better understanding of the mode of anti-cancer actions of BEC</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">,</span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;"> has led to the treatment of a patient who refused to have surgery for her clinically diagnosed stage II melanoma. </span><b><span style="font-family:Verdana;">Treatment: </span></b><span style="font-family:Verdana;">A 67-year woman had a birthmark that developed into a clinically diagnosed stage II melanoma and was treated with topical application of Curaderm twice daily for 7 weeks. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> The pattern of response of the melanoma to Curaderm therapy was similar to that observed when basal cell carcinoma is treated with Curaderm. The melanoma responded rapidly to the treatment and in 7 weeks the lesion was removed with no demonstrable side effects. The cosmetic end result was very acceptable. </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"> The clinical resolution of the melanoma with Curaderm pharmacotherapy conforms to the cell culture and animal obse展开更多
Non-melanoma skin cancer(NMSC) is one of the most common cancers in the US, although the role of obesity in skin cancer remains unclear. In vivo studies have consistently demonstrated that obese mice challenged with U...Non-melanoma skin cancer(NMSC) is one of the most common cancers in the US, although the role of obesity in skin cancer remains unclear. In vivo studies have consistently demonstrated that obese mice challenged with UVB radiation show increased skin tumorigenesis in comparison with leaner control mice. Growing evidence suggests that enhanced inflammation, oxidative stress and impaired apoptosis may play important roles in the development of skin cancer. Interventions such as voluntary exercise and the surgical removal of parametrial fat have been demonstrated to be effective in reducing adipose tissue that may influence the development of skin cancer; however, these interventions are not achievable in all obese patients. Therefore, the use of dietary natural phytochemicals that may modify and reverse the deregulated molecular and epigenetic events related to obesity and cancer development might represent a potential therapeutic modality due to their potential efficacy and low toxicity. In this review, we aim to provide the molecular and epigenetic basis of the NMSC-obesity relationship and to highlight the potential anti-cancer chemopreventive benefits of dietary phytochemicals such as sulforaphane and epigallocatechin-3-gallate.展开更多
Background: Reviewing and analyzing the Clinico-pathologic aspects of non-melanoma skin cancer of the head and neck (NMSCHN), type of management, prognostic factors, and disease-free survival (DFS) in a period of 5 ye...Background: Reviewing and analyzing the Clinico-pathologic aspects of non-melanoma skin cancer of the head and neck (NMSCHN), type of management, prognostic factors, and disease-free survival (DFS) in a period of 5 years at the National Cancer Institute—Cairo University—Egypt. Materials and Methods: A retrospective study of two hundred patients with NMSCHN was treated at the National Cancer Institute—Cairo University—Egypt from January 2008 to December 2012. The mean follow-up was 6 months (1 - 84 months). Results: 117 males and 83 females with 90% ≥ 50 years old. The scalp (27.5%), the periorbital region (13%), the cheek (12.5%) and the nose (12.5%) are the main anatomical sites affected. BCC represented 71.5% with nodular type (79%) predominance;SCC represented 21% with GII (61.1%) the commonest grade. Surgery was the main modality of treatment (93%) with local flaps only (63.9%) and primary closure (14.7%) were the main surgical options following wide local excision. Positive and close margins were detected in 23.5% of excised specimens. No significant association was found between disease-free survival (DFS) and pathology, treatment modality, the occurrence of complications or safety margin status. Conclusion: NMSCHN lesions should be surgically excised in specialized high volume centers with readily available peripheral margin control and should be operated by senior experienced surgeons.展开更多
Objective To show the distribution of facial exposure to non-melanoma biologically effective UV irradiance changes by rotation angles. Methods This study selected the cheek, nose, and forehead as representative facial...Objective To show the distribution of facial exposure to non-melanoma biologically effective UV irradiance changes by rotation angles. Methods This study selected the cheek, nose, and forehead as representative facial sites for UV irradiance measurements, which were performed using a rotating manikin and a spectroradiometer. The measured UV irradiance was weighted using action spectra to calculate the biologically effective UV irradiances that cause non-melanoma （UVBEnon.rnel） skin cancer. The biologically effective UV radiant exposure （HBEnon-mel） was calculated by summing the UVBEnon-mel data collected over the exposure period. Results This study revealed the following： （1） the maximum cheek, nose and forehead exposure UVA and UVB irradiance times and solar elevation angles （SEA） differed from those of the ambient UV irradiance and were influenced by the rotation angles; （2） the UV irradiance exposure increased in the following order： cheek 〈 nose 〈 forehead; （3） the distribution of UVBEnon-mel irradiance differed from that of unweighted UV radiation （UVR） and was influenced by the rotation angles and exposure times; and （4） the maximum percentage decreases in the UVBEnon-melradiant exposure for the cheek, nose and forehead from 0° to 180° were 48.41%, 69.48% and 71.71%, respectively. Conclusion Rotation angles relative to the sun influence the face＇s exposure to non-melanoma biologically effective UV.展开更多
The management of non-melanoma skin cancers metastatic to the neck is challenging due to variability in biological behavior and patterns of regional lymphatic spread.Metastatic non-melanoma skin cancers to the parotid...The management of non-melanoma skin cancers metastatic to the neck is challenging due to variability in biological behavior and patterns of regional lymphatic spread.Metastatic non-melanoma skin cancers to the parotid and neck often behave aggressively,with a high incidence of local recurrence after treatment and reduced five-year survival outcomes.Patterns of lymphatic spread are different from those seen in mucosal squamous cell carcinoma,with higher prevalence of disease in the parotid and superficial lymphatics.These factors require that treatment is individualized to achieve optimal outcomes.Traditionally,the management of non-melanoma skin cancers metastatic to lymph nodes has involved surgical excision followed by adjuvant radiation therapy.However,novel systemic therapies are showing promising results and their role in the management of these cancers is evolving.展开更多
目的探讨程序性死亡受体1(PD-1)/程序性死亡配体1(PD-L1)抑制剂在非黑色素瘤治疗中所致白癜风的临床特点。方法检索中国知网、万方医学、PubMed、Embase、Web of Science建库至2022年7月31日收录的PD-1/PD-L1抑制剂在非黑色素瘤中所致...目的探讨程序性死亡受体1(PD-1)/程序性死亡配体1(PD-L1)抑制剂在非黑色素瘤治疗中所致白癜风的临床特点。方法检索中国知网、万方医学、PubMed、Embase、Web of Science建库至2022年7月31日收录的PD-1/PD-L1抑制剂在非黑色素瘤中所致白癜风的病例报告类文献进行描述性统计分析。结果纳入分析的患者共25例,其中男性18例,女性7例;年龄32~79岁;25例患者首次使用PD-1/PD-L1抑制剂至发生白癜风最短时间为6 d,最长时间为5年,中位发生时间为用药后5个月。白癜风主要分布在头皮、面部、手部、四肢和躯干,可伴有其他免疫相关性不良事件,以甲状腺居多;皮肤活检表现为病变及病灶周围皮肤黑色素细胞及黑色素的缺失。20名患者进行了疗效评估,完全缓解6例,部分缓解3例,疾病稳定8例,疾病进展3例。结论白癜风是PD-1/PD-L1抑制剂在非黑色素瘤治疗中的一种罕见不良反应,白癜风的发生可能与良好的临床结果相关。展开更多
The purpose of this study was to investigate the clinical efficacy of photodynamic combined freezing in patients with non-melanoma skin cancer(NMSC).First,according to the treatment regimen,96 patients with NMSC were ...The purpose of this study was to investigate the clinical efficacy of photodynamic combined freezing in patients with non-melanoma skin cancer(NMSC).First,according to the treatment regimen,96 patients with NMSC were divided into study group(n=50)and control group(n=46).The control group was treated with 5-amino-ketovalic acid photodynamic therapy(ALAPDT),while the study group was treated with ala-PDT combined with cryotherapy.Visual analogue scale(VAS)scores,visual satisfaction,clinical efficacy,adverse reactions,and progression-free survival were compared between the two groups.The results showed that VAS score in the study group was slightly higher than that in the control group,but the difference was not statistically significant(P>0.05).The appearance satisfaction and total effective rate of patients in the study group were higher than those in the control group,and the difference was statistically significant(P<0.05).The total incidence of adverse reactions in the study group was slightly higher than that in the control group,but the difference was not statistically significant(P>0.05).3 years progressionfree survival time and 3 years progression-free survival rate were compared between the two groups,and the difference was not statistically significant(P>0.05).Therefore,the combination of PDT and cryotherapy for non-melanoma skin cancer has a good clinical effect,which is conducive to the recovery of skin lesions,high patient satisfaction,fewer adverse reactions,and longer progression-free survival.In addition,the combined therapy can provide a new treatment idea for non-melanoma skin cancer patients who are not suitable for surgical treatment.展开更多
文摘<strong>Background:</strong><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> There is ample evidence to support the safety and efficacy of the topical anticancer cream Curaderm in the treatment of non-melanoma skin cancers. Curaderm contains the natural glycoalkaloid solamargine in the form of BEC, which has been established as a novel antineoplastic agent. BEC is the initials of the inventor of the described technology. It is known that BEC expresses anti-melanoma properties in cell culture and animals. Because of potential metastasis, clinical work with BEC on melanoma was stalled. However, recent studies show that BEC has anti-metastatic properties and this, together with currently better understanding of the mode of anti-cancer actions of BEC</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">,</span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;"> has led to the treatment of a patient who refused to have surgery for her clinically diagnosed stage II melanoma. </span><b><span style="font-family:Verdana;">Treatment: </span></b><span style="font-family:Verdana;">A 67-year woman had a birthmark that developed into a clinically diagnosed stage II melanoma and was treated with topical application of Curaderm twice daily for 7 weeks. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> The pattern of response of the melanoma to Curaderm therapy was similar to that observed when basal cell carcinoma is treated with Curaderm. The melanoma responded rapidly to the treatment and in 7 weeks the lesion was removed with no demonstrable side effects. The cosmetic end result was very acceptable. </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"> The clinical resolution of the melanoma with Curaderm pharmacotherapy conforms to the cell culture and animal obse
基金Institutional funds,R01-CA118947 and R01-CA152826 from the National Cancer Institute(NCI)R01AT007065 from the National Center for Complementary and Alternative Medicines(NCCAM)and the Office of Dietary Supplements(ODS)
文摘Non-melanoma skin cancer(NMSC) is one of the most common cancers in the US, although the role of obesity in skin cancer remains unclear. In vivo studies have consistently demonstrated that obese mice challenged with UVB radiation show increased skin tumorigenesis in comparison with leaner control mice. Growing evidence suggests that enhanced inflammation, oxidative stress and impaired apoptosis may play important roles in the development of skin cancer. Interventions such as voluntary exercise and the surgical removal of parametrial fat have been demonstrated to be effective in reducing adipose tissue that may influence the development of skin cancer; however, these interventions are not achievable in all obese patients. Therefore, the use of dietary natural phytochemicals that may modify and reverse the deregulated molecular and epigenetic events related to obesity and cancer development might represent a potential therapeutic modality due to their potential efficacy and low toxicity. In this review, we aim to provide the molecular and epigenetic basis of the NMSC-obesity relationship and to highlight the potential anti-cancer chemopreventive benefits of dietary phytochemicals such as sulforaphane and epigallocatechin-3-gallate.
文摘Background: Reviewing and analyzing the Clinico-pathologic aspects of non-melanoma skin cancer of the head and neck (NMSCHN), type of management, prognostic factors, and disease-free survival (DFS) in a period of 5 years at the National Cancer Institute—Cairo University—Egypt. Materials and Methods: A retrospective study of two hundred patients with NMSCHN was treated at the National Cancer Institute—Cairo University—Egypt from January 2008 to December 2012. The mean follow-up was 6 months (1 - 84 months). Results: 117 males and 83 females with 90% ≥ 50 years old. The scalp (27.5%), the periorbital region (13%), the cheek (12.5%) and the nose (12.5%) are the main anatomical sites affected. BCC represented 71.5% with nodular type (79%) predominance;SCC represented 21% with GII (61.1%) the commonest grade. Surgery was the main modality of treatment (93%) with local flaps only (63.9%) and primary closure (14.7%) were the main surgical options following wide local excision. Positive and close margins were detected in 23.5% of excised specimens. No significant association was found between disease-free survival (DFS) and pathology, treatment modality, the occurrence of complications or safety margin status. Conclusion: NMSCHN lesions should be surgically excised in specialized high volume centers with readily available peripheral margin control and should be operated by senior experienced surgeons.
基金supported by the National Natural Science Foundation of China(No.81273034)Program for Liaoning Innovative Research Team in University(Grant number LT2015028)
文摘Objective To show the distribution of facial exposure to non-melanoma biologically effective UV irradiance changes by rotation angles. Methods This study selected the cheek, nose, and forehead as representative facial sites for UV irradiance measurements, which were performed using a rotating manikin and a spectroradiometer. The measured UV irradiance was weighted using action spectra to calculate the biologically effective UV irradiances that cause non-melanoma （UVBEnon.rnel） skin cancer. The biologically effective UV radiant exposure （HBEnon-mel） was calculated by summing the UVBEnon-mel data collected over the exposure period. Results This study revealed the following： （1） the maximum cheek, nose and forehead exposure UVA and UVB irradiance times and solar elevation angles （SEA） differed from those of the ambient UV irradiance and were influenced by the rotation angles; （2） the UV irradiance exposure increased in the following order： cheek 〈 nose 〈 forehead; （3） the distribution of UVBEnon-mel irradiance differed from that of unweighted UV radiation （UVR） and was influenced by the rotation angles and exposure times; and （4） the maximum percentage decreases in the UVBEnon-melradiant exposure for the cheek, nose and forehead from 0° to 180° were 48.41%, 69.48% and 71.71%, respectively. Conclusion Rotation angles relative to the sun influence the face＇s exposure to non-melanoma biologically effective UV.
文摘The management of non-melanoma skin cancers metastatic to the neck is challenging due to variability in biological behavior and patterns of regional lymphatic spread.Metastatic non-melanoma skin cancers to the parotid and neck often behave aggressively,with a high incidence of local recurrence after treatment and reduced five-year survival outcomes.Patterns of lymphatic spread are different from those seen in mucosal squamous cell carcinoma,with higher prevalence of disease in the parotid and superficial lymphatics.These factors require that treatment is individualized to achieve optimal outcomes.Traditionally,the management of non-melanoma skin cancers metastatic to lymph nodes has involved surgical excision followed by adjuvant radiation therapy.However,novel systemic therapies are showing promising results and their role in the management of these cancers is evolving.
文摘目的探讨程序性死亡受体1(PD-1)/程序性死亡配体1(PD-L1)抑制剂在非黑色素瘤治疗中所致白癜风的临床特点。方法检索中国知网、万方医学、PubMed、Embase、Web of Science建库至2022年7月31日收录的PD-1/PD-L1抑制剂在非黑色素瘤中所致白癜风的病例报告类文献进行描述性统计分析。结果纳入分析的患者共25例,其中男性18例,女性7例;年龄32~79岁;25例患者首次使用PD-1/PD-L1抑制剂至发生白癜风最短时间为6 d,最长时间为5年,中位发生时间为用药后5个月。白癜风主要分布在头皮、面部、手部、四肢和躯干,可伴有其他免疫相关性不良事件,以甲状腺居多;皮肤活检表现为病变及病灶周围皮肤黑色素细胞及黑色素的缺失。20名患者进行了疗效评估,完全缓解6例,部分缓解3例,疾病稳定8例,疾病进展3例。结论白癜风是PD-1/PD-L1抑制剂在非黑色素瘤治疗中的一种罕见不良反应,白癜风的发生可能与良好的临床结果相关。
文摘The purpose of this study was to investigate the clinical efficacy of photodynamic combined freezing in patients with non-melanoma skin cancer(NMSC).First,according to the treatment regimen,96 patients with NMSC were divided into study group(n=50)and control group(n=46).The control group was treated with 5-amino-ketovalic acid photodynamic therapy(ALAPDT),while the study group was treated with ala-PDT combined with cryotherapy.Visual analogue scale(VAS)scores,visual satisfaction,clinical efficacy,adverse reactions,and progression-free survival were compared between the two groups.The results showed that VAS score in the study group was slightly higher than that in the control group,but the difference was not statistically significant(P>0.05).The appearance satisfaction and total effective rate of patients in the study group were higher than those in the control group,and the difference was statistically significant(P<0.05).The total incidence of adverse reactions in the study group was slightly higher than that in the control group,but the difference was not statistically significant(P>0.05).3 years progressionfree survival time and 3 years progression-free survival rate were compared between the two groups,and the difference was not statistically significant(P>0.05).Therefore,the combination of PDT and cryotherapy for non-melanoma skin cancer has a good clinical effect,which is conducive to the recovery of skin lesions,high patient satisfaction,fewer adverse reactions,and longer progression-free survival.In addition,the combined therapy can provide a new treatment idea for non-melanoma skin cancer patients who are not suitable for surgical treatment.
